In8bio Inc Stock Performance
| INAB Stock | USD 0.28 0.01 3.45% |
On a scale of 0 to 100, In8bio holds a performance score of 2. The company owns a Beta (Systematic Risk) of -2.99, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning In8bio are expected to decrease by larger amounts. On the other hand, during market turmoil, In8bio is expected to outperform it. Please check In8bio's information ratio, treynor ratio, and the relationship between the downside deviation and total risk alpha , to make a quick decision on whether In8bio's current price history will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in In8bio Inc are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, In8bio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | IN8bio dips 9, prices 12.4M private placement | 10/01/2024 |
2 | Disposition of 81967 shares by William Ho of In8bio at 1.25 subject to Rule 16b-3 | 10/04/2024 |
3 | INAB Stock Hits 52-Week Low at 0.23 Amid Market Challenges - Investing.com | 10/08/2024 |
4 | Acquisition by Brandt Peter C. of 253164 shares of In8bio at 0.395 subject to Rule 16b-3 | 11/01/2024 |
5 | IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology Annual Meeting | 11/05/2024 |
6 | IN8bio stock target cut, analyst sustains buy rating on Q4 loss | 11/13/2024 |
7 | IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology Annual Meeting | 11/25/2024 |
8 | IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 A... | 12/10/2024 |
| Begin Period Cash Flow | 18.4 M |
In8bio |
In8bio Relative Risk vs. Return Landscape
If you would invest 31.00 in In8bio Inc on September 14, 2024 and sell it today you would lose (3.00) from holding In8bio Inc or give up 9.68% of portfolio value over 90 days. In8bio Inc is currently generating 0.4642% in daily expected returns and assumes 12.4782% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than In8bio, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
In8bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for In8bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as In8bio Inc, and traders can use it to determine the average amount a In8bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0372
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INAB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.48 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.46 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average In8bio is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of In8bio by adding it to a well-diversified portfolio.
In8bio Fundamentals Growth
In8bio Stock prices reflect investors' perceptions of the future prospects and financial health of In8bio, and In8bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on In8bio Stock performance.
| Return On Equity | -1.8 | ||||
| Return On Asset | -0.78 | ||||
| Current Valuation | 24.75 M | ||||
| Shares Outstanding | 72.48 M | ||||
| Price To Book | 2.45 X | ||||
| EBITDA | (28.5 M) | ||||
| Net Income | (30.01 M) | ||||
| Cash And Equivalents | 25.74 M | ||||
| Cash Per Share | 1.37 X | ||||
| Total Debt | 4.89 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.08 X | ||||
| Book Value Per Share | 0.58 X | ||||
| Cash Flow From Operations | (23.34 M) | ||||
| Earnings Per Share | (0.74) X | ||||
| Market Capitalization | 23.27 M | ||||
| Total Asset | 33.71 M | ||||
| Retained Earnings | (91.22 M) | ||||
| Working Capital | 19.23 M | ||||
About In8bio Performance
By analyzing In8bio's fundamental ratios, stakeholders can gain valuable insights into In8bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if In8bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if In8bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 51.33 | 45.62 | |
| Return On Tangible Assets | (0.89) | (0.93) | |
| Return On Capital Employed | (1.07) | (1.12) | |
| Return On Assets | (0.89) | (0.93) | |
| Return On Equity | (1.20) | (1.14) |
Things to note about In8bio Inc performance evaluation
Checking the ongoing alerts about In8bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for In8bio Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| In8bio Inc had very high historical volatility over the last 90 days | |
| In8bio Inc has some characteristics of a very speculative penny stock | |
| In8bio Inc has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| In8bio Inc currently holds about 25.74 M in cash with (23.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| In8bio Inc has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting |
- Analyzing In8bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether In8bio's stock is overvalued or undervalued compared to its peers.
- Examining In8bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating In8bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of In8bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of In8bio's stock. These opinions can provide insight into In8bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |